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Abstract
Background: Detection of tumor-associated genetic
alterations in plasma of cancer patients has recently
been suggested to be an accurate method for detect-
ing early or recurrent cancer.
Methods: We performed quantitative real-time PCR
for MYC and GAPDH in tissue and plasma samples of
57 patients with gastric cancer and in plasma of 79
cancer-free individuals. We also performed two-color
MYC fluorescence in situ hybridization (FISH) in tissue
from the 57 patients with gastric cancer.
Results: The tissue MYC/GAPDH ratio by real-time
PCR was significantly correlated with MYC status by
FISH (p-0.001). The mean ratio of plasma MYC/
GAPDH was 5.226"3.578 (range: 1.25–18.35) in gas-
tric cancer patients, and 2.436"0.881 (range: 1.00–
5.00) in the healthy volunteers (p-0.001). We used
receiver-operating characteristics (ROC) curve analy-
sis to select two optimal plasma MYC/GAPDH cut-offs
of 2.725 and 5.225. The sensitivity and specificity were
75.4% and 76.9% at 2.725, 38.6% and 100% at 5.225,
respectively. The plasma MYC/GAPDH ratio from
cancer patients was significantly correlated with the
tissue MYC/GAPDH ratio (ps0.009), and tissue MYC
status by FISH (ps0.024).
Conclusions: These findings suggest that the plasma
MYC/GAPDH ratio, as determined by real-time PCR,
may be an alternative non-invasive approach for
detecting gastric cancer.
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Introduction
Gene amplification and deletion plays an important
role in the pathogenesis of solid tumors. The MYC
gene is a known oncogene that encodes a transcrip-
tion factor that plays an essential role in cell prolif-
eration, cell growth, differentiation and apoptosis (1).
Oncogenic alterations in MYC are induced by events
such as point mutations, gene amplification, trans-
location, over expression, enhanced translation and
increased protein stability. The most common MYC
aberration in solid tumors is gene amplification (2). It
is possible to detect MYC amplification by southern
blotting, fluorescence in situ hybridization (FISH),
chromogenic in situ hybridization and quantitative
PCR. FISH has been universally accepted as the stan-
dard method for detection of gene amplification, and
amplification of MYC was found by FISH in 15%–30%
of gastric cancers (3–6). Real-time PCR is a new meth-
od for quantitative DNA analysis, and has been
reported to be a highly reproducible method for deter-
mining gene amplification, including HER-2 and MYC
status (7, 8).
Gastric cancer is the fourth most common cancer
and the second leading cause of cancer deaths world-
wide (9, 10). Curative resection is the most effective
treatment for gastric cancer, and the 5-year survival
rate is more than 90% when gastric cancer is detected
early. However, more than 50% of gastric cancer
patients with advanced stage will die of recurrent or
metastatic disease (11, 12). Earlier detection of gastric
cancer would improve the efficacy of treatment and
disease management. Thus, it is necessary to identify
and develop reliable diagnostic markers for early
detection of gastric cancer. Detectable tumor-associ-
ated DNA sequences have been demonstrated in the
plasma of cancer patients (13). Thus, it has been pos-
sible to identify tumor-specific microsatellite altera-
tion, ras gene mutations, and promoter methylation
in the serum and/or plasma DNA of patients with dif-
ferent cancers (14–16). Using Epstein-Barr virus (EBV)
DNA as the target genome, circulating EBV DNA has
been shown to be a useful tumor marker for EBV-pos-
itive gastric cancers. This suggests the presence of
circulating tumor-associated DNA in gastric cancer
patients (17). Measurement of serum MYCN status
using DNA-based real-time PCR has recently been
reported to be an accurate method for assessing
MYCN status in patients with neuroblastoma (18).
In this study, in order to demonstrate tumor-asso-
ciated DNA in the plasma of gastric cancer patients,
we performed quantitative real-time PCR for MYC and
a reference gene in tissue and plasma samples of 57
patients with gastric cancer. We also performed
measurements in the plasma of 79 cancer-free indi-
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viduals. In addition, we performed two-color FISH in




A total of 86 patients with gastric cancer underwent gastric
resection at Seoul National University Bundang Hospital
between January and April, 2005. We obtained the matching
cell-free plasma samples of these same patients by collect-
ing remnants of pre-operative blood samples. Using this
technique, we obtained 57 cases (66.3%) of gastric cancer
tissue and matching cell-free plasma samples. Thirty-eight
males and 19 females with a mean age ("SD) of 61.3"11.3
years were included. Depth of invasion and lymph node
metastasis was evaluated following review of the pathology
records (12). Thirty-two cases of early gastric cancer and 25
advanced cancers were represented. Tissue slides were
reviewed for histologic classifications according to the WHO
and Lauren’s classifications (11, 19). For the plasma samples
of disease-free controls, 39 anonymous age-matched healthy
volunteers were enrolled. They did not have any neoplasm
in their stomach or other organs.
In addition to the samples from gastric cancer patients and
healthy controls, we collected cell-free plasma samples from
patients with gastric adenoma and those with gastritis.
Blood samples from four patients with gastric adenoma
were collected using remnants of preoperative blood sam-
ples before endoscopic mucosal resection. All adenomas
were low-grade tubular adenomas without cancerous trans-
formation in any focus. Thirty-six patients with gastritis who
underwent routine gastroscopy and routine blood tests were
also enrolled. Of these patients with gastritis, ten were
infected with Helicobacter pylori, and nine patients had
intestinal metaplasia by histologic findings. Patients with
gastritis did not have any neoplasm in their stomach or other
organs.
For the positive MYC amplification control, we used the
gastric cancer cell line, SNU16, which has been reported to
have MYC amplification (20). This study was approved by
the institutional Review Board for human subject research at
Seoul National University Bundang Hospital.
Tissue array method
A tissue array block containing a total of 57 cases was pre-
pared as described previously (Superbiochips Laboratories,
Seoul, Korea) (21). A core tissue biopsy, 2 mm in diameter,
was taken from an individual paraffin-embedded gastric
tumor (donor block) and arranged in a recipient paraffin
block (tissue array block) using a trephine. Cases were con-
sidered adequate if tumor occupied more than 10% of the
core area. Four mm sections were cut from each tissue array
block, deparaffinized, and then dehydrated.
FISH analysis
Two-color FISH of tumor interphase nuclei was performed
using the LSI MYC (8q24.12–q24.13) and CEP8 probes (Vysis,
Downers Grove, IL, USA). The MYC specific locus probe was
labeled in orange, the chromosome eight centromere was
labeled in green, and the nuclei were counterstained in blue
(DAPI, Vysis, Downers Grove, IL, USA). The fluorescent
signals were counted in 2=20 non-overlapping nuclei per
tissue array core. The ratio between the MYC signals and the
chromosome eight centromere signals was established;
(i) ‘high amplification’ was considered to occur when this
ratio was G2: (ii) more than two signals accompanied by an
identical number of centromere signals in more than 60% of
tumor cells was considered ‘low amplification (polysomy)’:
and (iii) only two gene signals in more than 60% of the tumor
cells were scored as ‘non-amplified MYC (disomy)’ (22, 23).
DNA extraction from tissue and plasma samples
DNA from tissue of 57 patients with primary gastric cancer
was obtained after manual microdissection with hematoxy-
lin-eosin stained sections of the formalin-fixed, paraffin
embedded surgical specimens. This microdissection proce-
dure enabled more than 60% purity of the tumor cell popu-
lations to be obtained. The DNA was extracted using a
chelating ion exchange resin (InstaGene Matrix, Bio-Rad,
Hercules, CA, USA).
The plasma from 57 patients with gastric cancer, four
patients with gastric adenoma, 36 with gastritis, and 39
healthy persons was treated by filtration (Fisher Scientific,
Pittsburgh, PA, USA), and the plasma DNA was extracted
using a High Pure Viral Nucleic Acid kit (Roche, Penzberg,
Germany). The plasma DNA was extracted from all 57
plasma samples from patients with gastric cancer.
Real-time PCR analysis for relative gene copy
number quantification
Real-time quantitative TaqMan PCR was performed on each
sample using a Universal ProbeLibrary (UPL) (Roche) and
LightCycler 2.0 (Roche). In addition, to the MYC gene,
GAPDH was simultaneously measured as a reference gene.
The primer sets used were as follows: MYC forward, 59-CCT
CCC TCC ACT CGG AAG-39; MYC reverse, 59-TCT GAC ACT
GTC CAA CTT GAC C-39; GAPDH forward, 59-ACA CCC ACT
CCT CCA CCT TT-39; GAPDH reverse, 59-TGA CAA AGT GGT
CGT TGA GG-39 (Bioneer, Daejeon, Korea). The UPL probe
sequences were as follows: MYC (UPL 18), 59-tcc tgc tg-39;
GAPDH (UPL 45), 59-ctg ggg ct-39. All the reactions were
performed in a final volume of 20 mL that contained
5=LightCycler TaqMan Master 4 mL (Roche), UPL probe
0.4 mL, each primer 0.4 mL, and DNA 5 mL. All reactions were
performed using the same cycling conditions: 958C for 10 s,
558C for 30 s, and 728C for 1 min, for 45 cycles.
For each run, five dilutions of DNA of the stomach cancer
cell line (SNU16), which harbors a high-level MYC amplifi-
cation, were used to generate a gene-specific internal cali-
bration curve. Real-time PCR amplification efficiencies (E)
were determined according to the equation: Es10(–1/slope). As
a modification of the 2–DDCT method (24), we calculated the
relative gene copy number (termed MYC/GAPDH ratio) in the
test sample from the PCR efficiencies. These were deter-
mined for each run, and the crossing point (CP) deviations
of the target and reference genes in a control vs. a test
sample: E(CPmycyCPgapdh)controly(CPmycyCPgapdh)test (8).
Statistical analysis
Patients with gastric cancer and cancer-free individuals were
compared with respect to plasma MYC/GAPDH ratio by the
independent t-test. The plasma MYC/GAPDH ratio was eval-
uated using receiver-operating characteristic (ROC) curve
analysis and the area under the ROC curve (AUC) used for
statistical comparisons. Correlation coefficients between the
plasma MYC/GAPDH ratio and the clinicopathologic factors
were estimated by Pearson’s correlation analysis. Results
were considered to be statistically significant at p-0.05. All
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Table 1 Correlation between MYC status of gastric cancer tissue, determined by FISH, and clinicopathologic parameters.
MYC status by FISH Total p-Value
Non- Low High
amplified amplification amplification
Age 57.28"13.09 64.76"7.654 67.43"6.133 61.28"11.32 0.019
Tumor size 4.886"3.752 4.600"3.289 3.543"2.351 4.616"3.417 NS
Lauren classification
Intestinal 9 13 6 28 0.012
Diffuse 20 8 1 29
Tumor progression
Early gastric cancer (EGC) 15 13 4 32 NS
Advanced gastric cancer (AGC) 14 8 3 25
Lymph node metastasis
Absent 15 12 6 33 NS
Present 14 9 1 24
Total 29 21 7 57
NS, not significant (p)0.05). FISH, fluorescence in situ hybridization.
Figure 1 MYC status by FISH and quantitative real-time PCR.
(A) MYC status by FISH analysis (=400); the gastric cancer cell-line (SNU16) as the positive control (left), non-amplified gastric
cancer (center), and highly amplified gastric cancer (right). (B) Amplification curves of MYC (left) and GAPDH (right) by
quantitative real-time PCR.
statistical analyses were conducted using SPSS 15.0 statis-
tical software program (SPSS, Chicago, IL, USA).
Results
MYC status by FISH and real-time quantitative PCR
in gastric cancer tissues
Of the 57 gastric cancer tissues, high amplification of
MYC gene was found in seven specimens (12.3%) by
FISH, and low amplification of MYC in 21 (36.8%)
(Figure 1). Gastric cancers with high amplification and
low amplification of MYC had a tendency to be the
intestinal type, according to Lauren’s classification
(ps0.012) (Table 1).
Real-time quantitative PCR was performed on sev-
en gastric cancer tissue samples with high amplifi-
cation of MYC, 21 cancer tissue samples with low
amplification, and 29 cancer tissues with non-ampli-
fied MYC (Figure 1). The MYC/GAPDH ratio in gastric
cancer tissues with high amplification was signifi-
cantly higher than the ratio seen in cancer tissues
with low amplification and non-amplified MYC (Table
2). The ROC curve was obtained by comparing the
tissues with high amplification, low amplification and
non-amplified MYC. The optimized MYC/GAPDH ratio
for MYC amplification in gastric cancer tissue was 9.5
(100% sensitivity and 100% specificity).
MYC status in cell-free plasma DNA of gastric
cancer patients and controls
In plasma samples collected from 57 gastric cancer
patients prior to surgery and from 79 individuals who
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Table 2 The tissue MYC/GAPDH ratio, measured by quan-
titative real-time PCR, in MYC-amplified and non-amplified
gastric cancer using FISH.
FISH n Mean ratio of tissue p-Value
MYC/GAPDH (range)
Non-amplified 29 3.541"1.804 (1.10–7.60)
Low amplification 21 5.124"1.975 (2.40–9.00) -0.001
High amplification 7 11.83"1.267 (10.00–13.20)
FISH, fluorescence in situ hybridization.
Figure 2 Scatter plots and receiver-operating characteristics (ROC) curve.
(A) Scatter plot of the plasma MYC/GAPDH ratio as determined by real-time PCR for the 39 healthy volunteers, 36 gastritis
patients, four adenoma patients, 32 early gastric cancer patients, and 25 advanced cancer patients. (B) Scatter plot of the
MYC/GAPDH ratio as determined by real-time PCR for the plasma samples of the 79 cancer-free individuals (left), for the
plasma samples of the 57 gastric cancer patients (center), and for the tissue samples of the 57 cancer patients (right). (C) ROC
curve obtained by comparing the cell-free plasma ratio of MYC/GAPDH between the 57 gastric cancer patients and 39 healthy
controls. EGC, early gastric cancer; AGC, advanced gastric cancer; AUC, area under the ROC curve.
were cancer-free (four gastric adenoma patients, 36
gastritis patients, and 39 healthy volunteers), the
mean ratio of plasma MYC/GAPDH determined by
real-time PCR was 5.226"3.578 (range: 1.25–18.35) in
the patients with gastric cancer, 2.436"0.881 (range:
1.00–5.00) in the healthy volunteers, 2.550"1.162
(range: 0.50–5.40) in patients with gastritis, and
2.800"0.356 (range: 2.30–3.10) in patients with
adenoma. The mean ratio of plasma MYC/GAPDH
between patients with gastric cancer and cancer-free
individuals was statistically significant (p-0.001). The
mean ratio of plasma MYC/GAPDH was 5.791"4.195
(range: 1.55–18.35) in patients with early gastric can-
cer, and 4.504"2.485 (range: 1.25–11.50) in plasma of
patients with advanced cancer (p)0.05) (Figure 2).
The ROC curve for the ratio of plasma MYC/GAPDH
was obtained by comparing the gastric cancer
patients and age-matched healthy volunteers (Figure
2). The ROC curve showed that classification using the
plasma MYC/GAPDH ratio had significant discrimi-
nating ability to differentiate gastric cancer patients
from healthy controls. We selected two cut-offs of the
plasma MYC/GAPDH ratio of 2.725 and 5.225. The
sensitivity and specificity were 75.4% and 76.9% at a
2.725 cut-off value and 38.6% and 100% at a 5.225 cut-
off value, respectively (Table 3). Twenty-two (38.6%)
of 57 patients with gastric cancer had an elevated
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Table 3 Sensitivity and specificity for diagnosis of gastric
cancer using the plasma MYC/GAPDH ratio at two different
cut-off values.
Cut-off Sensitivity, Specificity, PPV, NPV,
% % % %
2.725 75.4 76.9 82.7 68.2
5.225 38.6 100 100 52.7
Cut-off, cut-off value of plasma MYC/GAPDH ratio; PPV, pos-
itive predictive value; NPV, negative predictive value.
Table 4 Correlation coefficients between the MYC/GAPDH ratio in the cell-free plasma DNA and clinicopathologic parameters.
Parameters Plasma MYC/GAPDH ratio
Correlation coefficient p-Value
Tissue MYC/GAPDH ratio by real-time PCR 0.342 0.009a
Tissue MYC status by FISH 0.240 0.024b
Age 0.008 0.955
Lauren classification –0.051 0.706
Size –0.015 0.912
Depth of invasion –0.099 0.463
Lymph node metastasis 0.029 0.831
Lymphatic invasion –0.144 0.285
Venous invasion –0.079 0.560
Cancer border 0.105 0.438
ap-0.01; bp-0.05. FISH, fluorescence in situ hybridization.
plasma MYC/GAPDH ratio using the cut-off of 5.225.
These 22 patients consisted of 13 with early gastric
cancer and nine with advanced cancer (ps0.722).
Correlation between plasma MYC status
and clinicopathologic characteristics
Table 4 shows the correlation coefficients between
the various clinicopathologic factors and the plasma
MYC/GAPDH ratio in patients with cancer. For factors
such as age, tumor size, depth, metastasis, histologic
type, and the tissue MYC/GAPDH ratio, the plasma
MYC/GAPDH ratio from the cancer patients was sig-
nificantly correlated with the tissue MYC/GAPDH
ratio (ps0.009) and the tissue MYC status by FISH
(ps0.024). The mean ratio of plasma MYC/GAPDH in
patients with non-amplified MYC (4.159"2.553) by
FISH was lower than in patients with low amplifica-
tion (6.024"4.029) and those with high amplification
of MYC (7.257"4.736) (ps0.016).
Evaluation of the two cut-offs of the plasma MYC/
GAPDH ratio between gastric cancer patients and
healthy volunteers showed that the mean ratio of tis-
sue MYC/GAPDH in cancer patients with a plasma
MYC/GAPDH ratio above 2.725 was 5.665"3.366. The
mean ratio of tissue MYC/GAPDH in the patients with
a plasma MYC/GAPDH ratio below 2.725 was 3.536"
1.805 (ps0.028). The mean ratio of tissue MYC/
GAPDH in cancer patients with a plasma MYC/GAPDH
ratio above 5.225 was 6.350"2.872, and the mean
ratio of tissue MYC/GAPDH in patients with a plasma
MYC/GAPDH ratio below 5.225 was 4.383"3.165
(ps0.022). Evaluating the two cut-offs (2.725 and
5.225) showed that the plasma MYC/GAPDH ratio did
not show any correlation with tumor size, depth,
lymph node metastasis, and angiolymphatic invasion
of gastric cancers (p)0.05) (data not shown).
The plasma MYC/GAPDH ratio was not correlated
with age of individuals that were cancer-free
(rs–0.10, ps0.381). For the 36 patients with gastritis,
the plasma MYC/GAPDH ratio did not show signifi-
cant correlation with H. pylori infection status
(rs–0.005, ps0.975) or intestinal metaplasia
(rs–0.160, ps0.353).
Discussion
Gastroscopy with biopsy, plasma carcinoembryonic
antigen (CEA) concentrations, and computed tomo-
graphy (CT) have all been used for making the diag-
nosis of gastric cancer. Early gastric cancer cannot be
easily diagnosed by plasma CEA concentrations or CT
due to their low sensitivity, and detecting early gastric
cancer by gastroscopy is dependent on the skill and
experience of the physician. While the 5-year survival
rate is more than 90% for patients detected early with
gastric cancer, more than 50% of patients with
advanced-stage gastric cancer will die of recurrent or
metastatic disease (11, 12). There are no additional
helpful diagnostic methods to help detect recurrence
of disease. Therefore, new diagnostic methods for
detecting early gastric cancer and disease recurrence
are needed. This study showed that higher levels of
the MYC/GAPDH ratio in cell-free plasma DNA could
be detected using real-time PCR in gastric cancer
patients, compared with cancer-free controls. We sug-
gest that plasma MYC status can be used as a new
approach for detecting gastric cancer.
Tumor-specific DNA has been detected in the plas-
ma of patients with cancer of the lung, head and neck,
breast, colon, and gastric cancer (13–18). This sug-
gests that cell-free plasma is a good source for detect-
ing cancer-specific DNA markers. The plasma DNA
concentrations in patients with gastric cancer were
recently reported to be significantly higher than those
of the control group, and the DNA integrity was also
higher in cancer patients than that of the controls (25).
DNA methylation status including p16 and p15, and
the detection of EBV DNA, have been used for the
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early detection of tumor-related DNA in the serum or
plasma of patients with gastric cancer (17, 26). Tumor-
specific microsatellite alterations and mutations in the
serum and/or plasma DNA of patients with different
cancers has been reported (14–16). We demonstrated
MYC amplification in the filtered plasma of gastric
cancer patients using real-time PCR. Thus, MYC
amplification in the plasma DNA may be used for
detecting gastric cancer. Other amplified genes in
plasma of gastric cancer patients includes C-MET,
k-sam, and HER-2. These may be candidates for use
in detection of gastric cancer.
We developed ROC curves by comparing the
plasma MYC/GAPDH ratio between gastric cancer
patients and healthy volunteers. We selected two
MYC/GAPDH cut-offs of 2.725 and 5.225. At the cut-
off of 5.225, the specificity and positive predictive val-
ue were high (100%), but the sensitivity was low
(38.6%). Of the 22 gastric cancer patients with a plas-
ma MYC/GAPDH ratio above 5.225, 13 patients had
early gastric cancer (p)0.05). In addition, the plasma
MYC/GAPDH ratio in gastric cancer patients was not
correlated with invasion depth, lymph node metasta-
sis or angiolymphatic invasion (p)0.05). We suggest
that early gastric cancer can be detected by the plas-
ma MYC/GAPDH ratio.
In this study, the plasma MYC/GAPDH ratio was
correlated with the tissue MYC/GAPDH ratio (corre-
lation coefficient: 0.342, ps0.009), and tissue MYC
status as determined by FISH (correlation coefficient:
0.240, ps0.024). However, correlation coefficients
were relatively low suggesting that plasma MYC
status is roughly correlated with the tissue MYC stat-
us in gastric cancer patients. There are a number of
possible reasons for this, including tumor volume,
angiogenesis capacity, and tumor apoptosis/necrosis.
In this study, tumor size, depth, and lymph node
metastasis were not significantly correlated with the
plasma MYC/GAPDH ratio. Therefore, the physiologi-
cal characteristics of the tumor including angiogene-
sis and apoptosis/necrosis may be more important for
predicting plasma MYC status compared with tumor
size or extent. In addition, the quantity and quality of
the DNA template extracted from plasma is likely to
differ from the quality of the original tumor tissue,
based on the time of collection, the content of DNase,
and other factors. The amount of DNA template
derived from normal proliferative/apoptotic cells is
also likely to be variable amongst patient plasma, and
may be another important reason for the results
obtained.
We performed real-time PCR for determining the
MYC status in gastric cancer tissue and we compared
it with the results of the FISH findings. The tissue
MYC/GAPDH ratio in cases with high amplification of
MYC by FISH was significantly higher than the tissue
MYC/GAPDH ratio in both the non-amplified cases
and low amplification cases. This result is generally
consistent with previous studies showing some gene
amplification in various tumors (7, 8, 27). Thus,
although FISH remains a standard method for deter-
mining gene amplification status, real-time PCR may
be an alternative to FISH for determining MYC status.
Various genetic alterations have been reported to
correlate with aggressive and invasive features in
gastric cancer, and many genetic alterations are fre-
quently found in advanced gastric cancer. Genetic
changes, found in both early and advanced gastric
cancer, could be helpful for early detection of gastric
cancer. The MYC alteration has been found in both
early and advanced gastric cancer in previous studies
(5), as well as this study. Therefore, MYC alterations
may be a good candidate for diagnosing gastric
cancer. Other studies have shown an association
between MYC amplification and clinicopathologic
features of gastric cancer. Calcagno et al. demonstrat-
ed MYC amplification in intestinal types of gastric
cancer by FISH (6). In this study, cases with high
amplification and low amplification had a higher
tendency of the intestinal type, supporting previous
results.
In summary, we performed quantitative real-time
PCR on tissue and plasma of 57 patients with gastric
cancer, and on plasma of 79 individuals that were
cancer-free in order to determine MYC status. The
plasma MYC/GAPDH ratio in the gastric cancer
patients was significantly higher than the plasma
MYC/GAPDH ratio in the healthy controls. The MYC/
GAPDH ratio in cell-free plasma DNA, as determined
by real-time PCR, may be an alternative non-invasive
approach for the detection of gastric cancer. The plas-
ma MYC/GAPDH ratio from cancer patients was sig-
nificantly correlated with the ratio of MYC/GAPDH in
cancer tissue.
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